A cohort study to evaluate persistence of hepatitis B immunogenicity after administration of hexavalent vaccines

[Guest guest]

http://www.biomedcentral.com/1471-2334/8/100/abstract

A cohort study to evaluate persistence of hepatitis B immunogenicity after

administration of hexavalent vaccines

Cristina Giambi , Antonino Bella , Antonella Barale , Domenico Montu ,

Marchisio , Maurizio Oddone , Salvatore Zito , Rapicetta , Paola Chionne ,

betta Madonna and Marta L Ciofi degli Atti

BMC Infectious Diseases 2008, 8:100doi:10.1186/1471-2334-8-100

Published: 28 July 2008

Abstract (provisional)

Background

In 2001, two hexavalent vaccines were licensed in Italy (Hexavac®, Infanrix

Hexa®), and since 2002 were extensively used for primary immunization in the

first year of life (at 3, 5, 11/12 months of age). In 2005, the market

authorization of Hexavac® was precautionary suspended by EMEA, because of

doubts on long-term protection against hepatitis B virus. The objectives of this

study were to evaluate the persistence of antibodies to anti-HBs, in children in

the third year of life, and to investigate the response to a booster dose of

hepatitis B vaccine.

Methods

Participant children were enrolled concomitantly with the offering of anti-polio

booster dose, in the third year of life. Anti-HBs titers were determined on

capillary blood samples. A booster dose of hepatitis B vaccine was administered

to children with anti-HBs titers

[Guest guest]

http://www.biomedcentral.com/1471-2334/8/100/abstract

A cohort study to evaluate persistence of hepatitis B immunogenicity after

administration of hexavalent vaccines

Cristina Giambi , Antonino Bella , Antonella Barale , Domenico Montu ,

Marchisio , Maurizio Oddone , Salvatore Zito , Rapicetta , Paola Chionne ,

betta Madonna and Marta L Ciofi degli Atti

BMC Infectious Diseases 2008, 8:100doi:10.1186/1471-2334-8-100

Published: 28 July 2008

Abstract (provisional)

Background

In 2001, two hexavalent vaccines were licensed in Italy (Hexavac®, Infanrix

Hexa®), and since 2002 were extensively used for primary immunization in the

first year of life (at 3, 5, 11/12 months of age). In 2005, the market

authorization of Hexavac® was precautionary suspended by EMEA, because of

doubts on long-term protection against hepatitis B virus. The objectives of this

study were to evaluate the persistence of antibodies to anti-HBs, in children in

the third year of life, and to investigate the response to a booster dose of

hepatitis B vaccine.

Methods

Participant children were enrolled concomitantly with the offering of anti-polio

booster dose, in the third year of life. Anti-HBs titers were determined on

capillary blood samples. A booster dose of hepatitis B vaccine was administered

to children with anti-HBs titers